The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
Author:
Publisher
Elsevier BV
Subject
Cancer Research
Reference225 articles.
1. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors;Gentzler;Immunotherapy,2016
2. The current landscape of immune checkpoint inhibition for solid malignancies;Keung;Surg. Oncol. Clin. N. Am.,2019
3. CXCL12 (SDF-1)/CXCR4 pathway in cancer;Teicher;Clin. Cancer Res.,2010
4. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow;Shakir;Pancreas,2015
5. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression;Sun;Cancer Metastasis Rev.,2010
Cited by 141 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies;Biomedicine & Pharmacotherapy;2024-09
2. Synthesis of selective BCL-XL PROTAC and potent antitumor activity in glioblastoma;2024-08-19
3. Lowering mortality risk in CR-HvKP infection in intestinal immunohistological and microbiota restoration;Pharmacological Research;2024-08
4. Blocking CXCR4–CARM1–YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis;Cancer Science;2024-07-28
5. Targeting cytokine and chemokine signaling pathways for cancer therapy;Signal Transduction and Targeted Therapy;2024-07-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3